Showing 31-40 of 7019 results for "".
Onexton Approved for Acne, Bellafill Debuts
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-onexton-approved-for-acne-bellafill-debuts/19019/In this edition of DermWireTV, from the editors of Practical Dermatology® magazine: Onexton is Valeant's fourth new approval in a year. We look at Suneva's renamed filler and the FDA's decision to grant breakthrough status to investigational atopic dermatitis treatment dupilumab. PLUS: This week'sAubio Launches, Updates from Prescriber's Choice, BioPharmX
https://practicaldermatology.com/topics/practice-management/dermwiretv-aubio-launches-updates-from-prescriber-s-choice-biopharmx/18584/In this edition of DermWireTV, Aubio launches OTC treatment for cold sores with backing from Paul Mitchell partner. Prescriber's Choice facilitates in-office prescription dispensing. BioPharmX enrolls phase 2b trial for topical minocycline and Merz acquires ONLight Sciences, maker of PFD patch for tTECHtonic Shifts: Big Data, AI, and Dermatology
https://practicaldermatology.com/topics/practice-management/techtonic-shifts-big-data-ai-and-dermatology/18428/Robots can diagnose skin malignancies. Big data may give insurers ammunition to reduce payments. And dermatologists are left dealing with the fall-out from the rapid evolution of technology. In this special edition of Derm Insider Mark Kaufmann, MD dives into the challenges facing the specialty andBiologics Preferred after MACE in PsO, Plus More
https://practicaldermatology.com/series/dermwire-tv/biologics-preferred-after-mace-in-pso-plus-more/37882/In this edition of DermwireTV, new research shows biologic use use after MACE is persistent, signaling strong patient preference; a new study shows that early stress may raise lifelong psoriasis risk; and a new C-Suite Chat highlights a new antibody showing promise in treating atopic dermatitisTo Be Shorr: Negotiate with Confidence
https://practicaldermatology.com/topics/practice-management/to-be-shorr-negotiate-with-confidence/18717/Knowing when and how to negotiate is key. Sometimes, the best outcome is possible when a third party negotiates on your behalf. Jay Shorr explains in this edition of To Be Shorr.Top Stories of 2014 and the Aesthetic Pipeline
https://practicaldermatology.com/topics/psoriasis/top-stories-of-2014-and-the-aesthetic-pipeline/18996/In this special edition of DermWireTV we take a look back at some of the biggest stories of 2014. Plus experts weigh in on the future of aesthetic medicine.Valeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicASDS BCC Recommendations; Bad Online Reviews for Derms
https://practicaldermatology.com/topics/practice-management/dermwiretv-asds-bcc-recommendations-bad-online-reviews-for-derms/18906/This edition of DermWireTV, from the editors of Practical Dermatology® magazine reviews the new ASDS Consensus Recommendation for the management of Basal Cell Carcinoma (BCC). An expert panel found Mohs micrographic surgery is highly cost effective. In other news, researchers find that dermatologistBest Practices: Allan Wirtzer, MD on Leadership
https://practicaldermatology.com/topics/practice-management/best-practices-allan-wirtzer-md-on-leadership/18592/Sometimes the most important role of a physician is leader. Whether in your practice or for your specialty overall, doctors must lead the charge forward. In this edition of Best Practices, host Joel L. Cohen, MD talks to Allan S. Wirtzer, MD about issues affecting medicine, including coding, and theDermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's lates